60 Degrees Pharmaceuticals Inc. Warrant (SXTPW)
Market Closed
9 Sep, 19:42
NASDAQ (CM) NASDAQ (CM) Primary $
0. 04
+0
+1.7442%
Pre Market
$
-0 -2% 0. 03
- Market Cap
- P/E Ratio
- Div Yield
1,653 Volume
- Eps
$ 0.03
Previous Close Investors:
Want to track SXTPW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
SXTPW closed yesterday higher at $0.04, an increase of 1.7442% from Tuesday's close, completing a monthly decrease of -30.4175% or -$0.02. Over the past 12 months, SXTPW stock lost -30.4175%.
SXTPW is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
SXTPW Chart
60 Degrees Pharmaceuticals Inc. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 145,969 | $5,400.92 | $5,108.91 | -$292.01 | -5.41% |
60 Degrees Pharmaceuticals Inc. Warrant (SXTPW) FAQ
What is the stock price today?
The current price is $0.04.
On which exchange is it traded?
60 Degrees Pharmaceuticals Inc. Warrant is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is SXTPW.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has 60 Degrees Pharmaceuticals Inc. Warrant ever had a stock split?
No, there has never been a stock split.
60 Degrees Pharmaceuticals Inc. Warrant Profile
| Pharmaceuticals Industry | Healthcare Sector | - CEO | NASDAQ (CM) Exchange | 83006G104 CUSIP |
| US Country | 2 Employees | - Last Dividend | - Last Split | - IPO Date |
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Contact Information
Address: -
Phone: -
